Actuate Therapeutics, Inc.
corporate_fare Company Profile
Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for ACTU at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Elraglusib Doubles Survival Rate in Pancreatic Cancer, Nature Medicine Publishes Pivotal Phase 2 Data
- Actuate Therapeutics Faces Going Concern Despite Positive Phase 2 Data and Recent Capital Raises
- Actuate Therapeutics Eyes $200M+ Pediatric PRV, Potentially Tripling Market Cap
- Actuate Therapeutics Launches Strategic Research to Combine Elraglusib with RAS Inhibitors, Targeting Resistance in Cancers
- Actuate Therapeutics Reports Positive Phase 2 Data for Elraglusib in Pancreatic Cancer, Showing Significant Overall Survival Benefit
Financial Snapshot
Fiscal year ended December 31, 2025
Net Income
-$22.23M
Diluted EPS
-$1.06
Op. Cash Flow
-$19.21M
Operating Income
-$22.5M
Cash & Equivalents
$13.16M
Debt / Equity
0.00×
Shares Outstanding
23.25M sh
Source: 10-K · filed 2026-03-26 · accession 0001683168-26-002257
show_chartPrice Chart
Loading chart...
feed ACTU - Filings & News (Page 2)
ACTU
Apr 14, 2026, 8:45 AM EDT
Price at Filing:
$1.81
Real-time Price:
$0.2004
Change:
-$1.61 (-89%)
Market Cap:
$13.604M
ACTU
Mar 26, 2026, 4:00 PM EDT
Price at Filing:
$2.27
Real-time Price:
$0.2004
Change:
-$2.07 (-91%)
Market Cap:
$13.604M
ACTU
Mar 24, 2026, 7:00 AM EDT
Price at Filing:
$2.44
Real-time Price:
$0.2004
Change:
-$2.24 (-92%)
Market Cap:
$13.604M
ACTU
Mar 09, 2026, 8:45 AM EDT
Price at Filing:
$2.84
Real-time Price:
$0.2004
Change:
-$2.64 (-93%)
Market Cap:
$13.604M
ACTU
Jan 12, 2026, 4:00 PM EST
Price at Filing:
$5.81
Real-time Price:
$0.2004
Change:
-$5.61 (-97%)
Market Cap:
$13.604M
ACTU
Jan 07, 2026, 12:45 PM EST
Price at Filing:
$6.73
Real-time Price:
$0.2004
Change:
-$6.53 (-97%)
Market Cap:
$13.604M